ID 110350
タイトルヨミ
シュウマツキ ガン ショウレイ ニオケル コウカルシウム ケッショウ ノ ケントウ
タイトル別表記
Hypercalcemia in patients with end-stage cancer
著者
三木, 仁司 近藤内科病院緩和ケア科
上田, 由利子 近藤内科病院緩和ケア科
荒瀬, 友子 近藤内科病院緩和ケア科
近藤, 彰 近藤内科病院総合内科
キーワード
hypercalcemia
cancer
end-stage
palliative care
bisphosphonates
資料タイプ
学術雑誌論文
抄録
Hypercalcemia develops in patients with advanced cancer and severely deteriorates their quality of life. This study aimed to evaluate the influence of hypercalcemia on the clinical course of patients with end-stage cancer. This retrospective study included data on 253 patients who had cancer and died in the palliative care unit at Kondo-Naika Hospital in 2008 and 2009. Of these patients, 16(6.3%) developed hypercalcemia during hospitalization before death. These 16 patients included5patients with lung cancer ;4 with esophageal cancer ;2 with pancreatic cancer ; and1patient each with liver cancer, breast cancer, gall bladder cancer, renal cancer, or gastric cancer. The incidence of esophageal cancer in the patients with hypercalcemia was significantly higher than that in the patients who did not have hypercalcemia(p<0.01). Of the 16 patients with hypercalcemia,10had bone metastasis, whereas the other6patients had hypercalcemia even without bone metastasis. The main symptom of hypercalcemia was drowsiness in7patients, delirium in6patients, and general fatigue in 3patients. Fifteen patients were treated using bisphosphonates. After the hypercalcemia was detected, the 16patients survived for only a short time, with a mean survival time of 16.9 days. In particular, the mean survival time of 7 patients who did not respond to treatment for hypercalcemia was only 6.0days, and1patient with a calcium level of 19.1 mg/dl died the day after zoledronic acid hydrate therapy was initiated. Thus, hypercalcemia in patients with end-stage cancer seems to indicate extremely critical conditions with the worst prognosis.
掲載誌名
四国医学雑誌
ISSN
00373699
cat書誌ID
AN00102041
出版者
徳島医学会
67
1-2
開始ページ
35
終了ページ
38
並び順
35
発行日
2011-04-25
フルテキストファイル
言語
jpn
著者版フラグ
出版社版